BPC-157: what the research actually says

What BPC-157 is

BPC-157 (Body Protection Compound-157) is a synthetic chain of 15 amino acids. It is a lab-made fragment derived from a protein found in human gastric juice — specifically, the sequence GEPPPGKPADDAGLV. It does not exist as a standalone molecule in the body; it is an engineered fragment that researchers have studied for effects on tissue, healing, and organ protection.² To understand where BPC-157 fits in the broader peptide landscape, our guide on what peptides are covers the category from the ground up.

How BPC-157 is thought to work

In animal studies, BPC-157 appears to influence multiple biological pathways simultaneously, which is part of what makes it scientifically interesting and commercially over-hyped. Researchers have identified several proposed mechanisms:

• Angiogenesis (new blood vessel formation): BPC-157 appears to upregulate vascular endothelial growth factor (VEGF) and activate its receptor (VEGFR2), promoting the growth of new capillaries into healing tissue.²
• Nitric oxide signaling: Studies in rodents suggest BPC-157 modulates nitric oxide synthesis, which affects blood flow and inflammatory signaling.
• Growth hormone receptor expression: Preclinical data shows BPC-157 may upregulate the growth hormone receptor in tendon fibroblasts — the cells responsible for building connective tissue — which could explain some of the tendon-healing observations.
• Cytoprotection: The compound was originally characterized in the context of gastric protection, where it appears to help protect stomach and intestinal lining against damage from anti-inflammatory drugs (NSAIDs) and other irritants.

All of these mechanisms have been described in cell cultures and animal models. Whether any of them operate meaningfully in the human body — and at what doses — is not established. Preclinical pharmacokinetic data shows that BPC-157 has a plasma half-life of under 30 minutes, yet produces biological effects lasting hours to days in animal studies — a disconnect that has significant implications for any future dosing strategy and that remains unexplained.³

What the evidence shows — and where it stops

The scale of BPC-157's preclinical evidence is not in question: over three decades of research have generated consistent findings across multiple organ systems in rodents. What that evidence base looks like in practice is a long list of animal studies demonstrating effects on tendon healing, muscle repair, gut protection, bone regeneration, and neurological tissue — followed by almost nothing in humans.²

The human evidence base is this thin: a 2026 peer-reviewed biopharmaceutical analysis published in Pharmaceutics (PMID 42198317) identified fewer than 30 subjects across three uncontrolled pilot studies as the entirety of the available human data. None of these studies employed standardized pharmaceutical preparations, none were placebo-controlled, and no Phase II clinical trial has been completed.³

Intramuscular bioavailability in animal models has been estimated at 14–51% depending on species, and no pharmaceutical-grade formulation has been developed or validated for human use.³ These are not minor footnotes — they mean there is no established dose, no validated delivery method, and no approved product, even setting aside the question of whether it works.

Evidence summary by claimed use

The table below summarizes the state of the research for each area where BPC-157 is commonly promoted. The grading reflects the highest-quality evidence available for each claim as of mid-2026.

Evidence grades follow GRADE conventions: Very Low (D) = evidence from animal or uncontrolled pilot studies only; strong possibility that further research will change the estimate substantially or that the true effect differs from the estimate.

The clinical trial history: why so few human studies exist

BPC-157 is not simply a novel compound that hasn't had time to reach human trials yet. It has had decades. The closest it came to formal clinical investigation was a program to study its protective effects in inflammatory bowel disease (IBD) under the name PL 14736. According to the U.S. Anti-Doping Agency, studies in this program "appear to have been cancelled or stopped without any published conclusions."⁵ The reasons for the cancellation were never publicly detailed.

A 2026 review in Pharmaceutics identified the primary barrier to clinical development: not a lack of biological activity in preclinical work, but "the absence of fundamental pharmaceutical science — characterized formulations, validated pharmacokinetics, and a coherent drug development strategy."³ In other words, BPC-157 lacks even the foundational drug-development work (stability testing, formulation science, excipient compatibility) that would normally precede a Phase I trial — despite more than 30 years of interest.

There is one recently registered trial: a study on BPC-157 for acute hamstring muscle strain (ClinicalTrials.gov NCT07437547) that was listed in 2026. This is early-stage and its results, if any, are not yet available. One pending registration does not change the overall picture.

Regulatory status: FDA and compounding

BPC-157 is not an FDA-approved drug for any indication. It has also been explicitly denied a legal pathway through compounding pharmacies. Under FDA rules governing bulk drug substances, a compound can only be prepared by licensed compounding pharmacies if it appears on an approved list — BPC-157 does not. When BPC-157 was nominated for formal regulatory review, the FDA published its assessment: compounded drugs containing BPC-157 "may pose risk for immunogenicity" and the agency found "no, or only limited, safety-related information for the proposed routes of administration," concluding it "lacks sufficient information to know whether the drug would cause harm when administered to humans."¹

This is why virtually all BPC-157 sold online carries the "research use only" label. That designation is not a regulatory category that permits human use — it is the mechanism by which vendors avoid drug-sales regulation while still reaching consumers who intend to use it on themselves. Our page on which peptides are FDA-approved covers this gray-market pathway in detail, and our telehealth vs. research vendors guide explains what the "research use only" label actually means.

Athletes and BPC-157: WADA's position

For anyone subject to drug testing in sport, BPC-157 carries a specific and straightforward risk: it is prohibited. The World Anti-Doping Agency lists BPC-157 under the S0 Unapproved Substances category of its Prohibited List — the broadest prohibition category, which covers any pharmacological substance not approved by a regulatory authority for human therapeutic use.⁵

The S0 category applies both in-competition and out-of-competition. An athlete who tests positive faces the same anti-doping sanctions as for any other banned substance — a therapeutic use exemption (TUE) is not available for an unapproved substance. The USADA has specifically named BPC-157 in its guidance and notes there is no TUE pathway for it.

This matters beyond professional sport. Many amateur sports organizations, including college athletics, adopt the WADA Prohibited List directly. Anyone subject to testing — at any level — should treat BPC-157 as prohibited.

What's actually known about safety

Animal studies have not generally reported major toxicity, and that fact often circulates as though it means BPC-157 is "safe." It doesn't. Safety in humans requires human data — on dosing, drug interactions, immunological reactions, product purity, and long-term effects. None of that data exists in usable form.

The FDA's published concern about immunogenicity is worth taking seriously. Peptides administered by injection can trigger immune responses, and the risk depends heavily on formulation quality, impurity profile, and whether the peptide forms aggregates in solution — none of which has been characterized for BPC-157 in any pharmaceutical-grade preparation.³ "No proof of harm" and "proof of safety" are categorically different things.

"You're really just experimenting with injecting amino acids into your body."

— Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School, on self-injecting unregulated peptides generally, in Harvard Health Publishing (July 2026). BPC-157 — sold almost entirely outside FDA oversight, with no validated pharmaceutical formulation — is precisely the kind of compound he describes.

Purity and the product you actually inject

Independent testing of peptides sold through "research use only" channels has repeatedly found discrepancies between labeled and actual content — products with less peptide than claimed, more than claimed, or contaminated with unlabeled compounds. Because BPC-157 cannot be sold as a drug in the United States, it has no requirement for third-party testing, current Good Manufacturing Practice (cGMP) compliance, or label accuracy.

When someone injects a research-vendor product, they are injecting whatever the vendor actually manufactured — which may or may not match the label. This is a distinct risk from the pharmacological question of whether BPC-157 itself would be safe in a pure, pharmaceutical-grade form. Our peptide side effects guide covers the contamination and injection-site risks that apply across this category.

If you're considering it anyway

The responsible path for anyone interested in BPC-157 is the same as for any experimental peptide: talk to a licensed clinician rather than self-sourcing from a vendor. A provider who specializes in peptide medicine can tell you what human evidence does and doesn't exist for your specific goal, what the realistic risk profile looks like, and whether there are better-studied options for your situation. If you are in a sport subject to anti-doping testing, the answer is unambiguous: BPC-157 is prohibited and the risk is not worth taking.

Our safest way to try peptides guide walks through how to vet a provider and what questions to ask. Our main are peptides safe page covers the category-level risks that apply to unregulated peptide use broadly, and are peptides legal covers where BPC-157 sits across different jurisdictions.